内异停方对子宫内膜异位症血清VEGF及在位内膜VEGFR-2的影响

Influences of Neiyiting Prescription on VEGF in Serum and VEGFR-2 in Eutopic Endometrium of Endometriosis Patients

目的:评价内异停方治疗子宫内膜异位症(EMs)疗效,观察内异停对EMs患者血清VEGF水平及在位内膜VEGFR-2的影响。方法:将76例EMs的患者分为两组,治疗组采用内异停方治疗,对照组采用桂枝茯苓胶囊治疗,2个月为1个疗程,观察2个疗程,评价临床疗效,并以ELISA方法检测血清VEGF,以免疫组化的方法检测在位内膜VEGFR-2的变化。结果:内异停方治疗EMs总有效率达88. 00%,优于对照组桂枝茯苓胶囊(58. 33%)(P <0. 05);内异停可明显降低血清CA125及VEGF水平(P <0. 05),与对照组相当;内异停组与对照组(未用药)在位内膜VEGFR-2比较,VEGFR-2表达明显下降。结论:内异停方治疗EMs有效,疗效优于桂枝茯苓胶囊,值得临床运用推广。内异停方可能通过降低EMs血清VEGF水平及在位内膜VEGFR-2水平发挥治疗作用。

Objective:It is to evaluate the curative effect of Neiyiting Prescription on endometriosis(EMs)and observe the influences of Neiyiting Prescription on the levels of VEGF in serum and VEGFR-2 in eutopic endometrium of endometriosis patients.Methods:A total of 76 EMs patients were divided into two groups,adopting Neiyiting Prescription for the therapy group and Cinnamom Twig Poria Capsule for the control group.Two months was as one course of treatment,observing for 2 courses.We evaluated the clinical curative effect,tested the change of VEGF in serum with ELISA method and the change of VEGFR-2 in eutopic endometrium with immunohistochemical method.Results:The total effective rate of Neiyiting Prescription for treatment of EMs was up to 88.00%,better than that of the control group(58.33%)(P<0.05).Neiyiting Prescription could obviously lower the levels of CA125 and VEGF in serum(P<0.05),equivalent to those of the control group.Compared with the control group(not given medicine)in terms of the VEGFR-2 in eutopic endometrium,Neiyiting Prescription group could obviously lower the expression of VEGFR-2.Conclusion:Neiyiting Prescription is effective in treatment of EMs,and has better curative effects than Cinnamom Twig Poria Capsule,and is worthy of clinical application and promotion.Neiyiting Prescription could possibly play a curative role by lowering the level of VEGF in serum and the level of VEGFR-2 in eutopic endometrium of EMs patients.